The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
iECURE's ECUR-506 has secured both the US FDA Regenerative Medicine Advanced Therapy designation and a UK Innovation Passport, positioning the...
A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
Regeneron Pharmaceuticals and Tessera Therapeutics have formed a global partnership to develop and commercialise TSRA-196, Tessera’s lead in vivo Gene...
Caribou Biosciences reported last week that its off-the-shelf, CRISPR-edited anti-CD19 CAR-T, vispa-cel (formerly CB-010), achieved response rates and...
CRISPR Therapeutics has presented preclinical data showing that its investigational therapy CTX460 can correct the SERPINA1 Z (E342K) mutation...
